Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful completion of a 300-gram scale-up batch of A83B4C63, the active pharmaceutical ingredient (API) supporting its proprietary ONC010 drug candidate. The batch, produced as part of Dalton Pharma Services’ Process Optimization and Intermediate Scale-Up Program, achieved approximately 99.3% purity with no detectable residual solvents following comprehensive quality control and Certificate of Analysis review. This milestone represents a significant advancement for the company’s PNKP inhibitor program, which targets solid tumors.
The scale-up campaign demonstrates the reproducibility and scalability of the manufacturing process, according to the company. This success is expected to support future analytical qualification, formulation development, engineering batch production, and GMP manufacturing activities ahead of planned First-in-Human studies. The achievement moves ONC010 closer to clinical testing, potentially offering a new treatment option for patients with solid tumors.
In addition to the manufacturing milestone, Onco-Innovations announced the appointment of Dave Antony as chief financial officer and corporate secretary, effective immediately. Antony succeeds Nico Mah and brings extensive financial expertise to guide the company through its next phase of growth. For more details, the full press release is available at https://ibn.fm/NJVb1.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumors. Investors can find the latest news and updates at https://ibn.fm/ONNVF.
